India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical laboratories, institutions, guilds and medical federations have taken on the task of designing programs to end health illiteracy in order to have informed, educated, knowledgeable and empowered communities where their health and wellbeing are concerned. 19 September 2024
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Targeted alpha therapy (TAT), or radioligand therapy, is a recent hot area that attracted big pharmas like Bristol Myers Squibb and Novartis. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
Scientists from the Russian Institute of Immunology of the Federal Medical and Biological Agency (FMBA) say they have created the world's first allergy vaccine. 30 August 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
One of the largest pharmaceutical production facilities in the Russian North-West region will soon be built in the city of Pushkino by the local drugmaker Active Component enterprise, The Pharma Letter’s local correspondent reports. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
The Russian Ministry of Health has registered the third Russian generic of the original drug Ozempic (semaglutide) from Danish drugmaker Novo Nordisk. 8 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024
Major pharmaceutical multinationals are looking to collaborate with Indian drug firms, leveraging their cost-efficient manufacturing capabilities, robust supply chains, and innovative research potential. 31 July 2024
The Russian government will be ready to significantly increase state procurements of drugs against hepatitis C in case of reduction price for them both by global drugmakers and Russian pharmaceutical companies. 31 July 2024
Some more essential drugs to treat cancer, malaria and epilepsy have been brought under price revision and, in certain cases, price control by the Indian government. The move has not gone down well with pharmaceutical companies, reports The Pharma Letter’s India correspondent. 21 September 2016
The Russian Ministry of Health is changing the existing procedure for the launch of new drugs on the domestic market, with the aim to speed their withdrawal, according to recent statements by Veronika Skvortsova, Russia’s Minister of Health, reports The Pharma Letter’s local correspondent. 21 September 2016
The Russian Ministry of Health is considering changing the conditions of tendering for the public procurement of high-priced drugs and vaccines, according to recent statements of an official spokesman of Veronika Skvortsova, Russia’s Minister of Health. 15 September 2016
In India, 33 drugs supplied to various government hospitals and stores in Arunachal Pradesh were found to be of sub-standard quality during laboratory tests. 30 August 2016
The Russian Federal Anti-Monopoly Service (FAS) has started investigations regarding the recent detection of a cartel in the Russian pharmaceutical market, which was created by some leading local drugmakers and global majors operating in the Russian market, according to press-service of the FAS, reports The Pharma Letter’s local correspondent. 26 August 2016
The Ministry of Health of Ukraine has officially approved the conduct of clinical trials of drugs imported to the country – the initiative that has long been lobbied by global pharmaceutical majors, operating in the country. 26 August 2016
Russian President Vladimir Putin has instructed the national Federal Anti-Monopoly Service (FAS) and the federal government to continue regular monitoring of drug prices in the domestic market, as well as their compliance with the current market realities. 8 August 2016
GlaxoSmithKline may consider the possibility of filing a petition to the Russian court with the complaint on the conditions of the forthcoming tender for the purchases of anti-pneumococcal vaccines for state needs in Russia. 1 August 2016
The Russian government is considering providing support to the domestic pharmaceutical producers planning to export their drugs, according to recent statements by Russia’s Prime-Minister Dmitry Medvedev, reports The Pharma Letter’s local correspondent. 1 August 2016
Even as a battle royal continues between Teva Pharmaceutical Industries (NYSE: TEVA) and Merck & C0 (NYSEL MRK) over the former’s alleged infringement of the latter’s Januvia (sitagliptin) patent in India, the recent decision of the Indian Patent Office to deny Cipla's patent application for an anti retroviral combination reveals its unbiased nature, reports The Pharma Letter’s India correspondent. 31 July 2016
Sales of mid- and high-priced drugs in Russia are steadily declining, due to the ongoing economic stagnation in the country and the consequences of the financial crisis, reports The Pharma Letter’s local correspondent. 21 July 2016
US drugmaker Abbott is considering further expanding of its Russian business during the next several years, according to recent statements of Michael Vormut, Abbott’s executive vice-president. 21 July 2016
The Russian government is considering introducing a three-stage procedure for the public procurement of drugs, according to recent statements of an official spokesman of Denis Manturov, Russia’s Minister of Industry and Trade. 12 July 2016
The Indian government is looking to widen the scope of price controls on pharmaceuticals. In a move that could create another potential hurdle for multinational drug companies doing business in India, the Department of Pharmaceuticals is examining a proposal to look into the pricing of patented drugs in the country, reports The Pharma Letter’s India correspondent. 11 July 2016
Russian pharmaceutical companies plan to significantly increase the volume of investments in the conduct of clinical trials of their drugs over the next few years, according to recent statements of drugmakers. 5 July 2016
Leading Russian biotech firm Biocad has filed a petition to the New York Federal Court against Swiss pharma giant Roche, accusing the company of setting monopoly-low prices for its products in Russia, with the aim of ruining business of local competitors, reports The Pharma Letter’s local correspondent. 14 June 2016
Several pharmaceutical companies in India, including Dr Reddy's, have been trying for months to recover funds from Venezuela. The nation is not the only one giving sleepless nights to Indian pharma exporters, struggling to counter an expected drop in export growth, reports The Pharma Letter’s India correspondent. 2 June 2016
The Russian government is considering subsidizing the production of cheap drugs, amid the fears of their disappearance from the market, according to recent statements of Arkady Dvorkovich, Russia’s Deputy Prime Minister, reports The Pharma Letter’s local correspondent. 2 May 2016